Eucalyptus gum

DB15537ApprovedInvestigationalOrganism Based Therapies

Eucalyptus gum: Overview.

Mechanism: Pharmacologically active on Transient receptor potential cation channel subfamily A member 1 and Transient receptor potential cation channel subfamily M member 8
Curator reviewed
First approval: Canada, 1999
Also known as: Eucalyptus · Eucalyptus globulus resin · Eucalyptus kino · Kino australiensis · Kino, eucalyptus

Resolves to

Compound

Clinical / RWD

Targets

What you can answer from here — as of July 08, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

7Marketed productsAcross 2 countries and 6 labellers

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Eucalyptus gum, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.